Old myocardial infarction

Researchers found that patients with persistently high levels of urinary albumin excretion in the long term are at high risk of new-onset heart failure. Preventive treatment associated with the lowering of urinary albumin excretion levels in these patients could reduce the risk of later heart failure or mortality. They say that an ounce of prevention is worth a pound of cure; knowing which preventive treatment to administer to which patient could undoubtedly up that yield. Now, an international research team led by Osaka University has identified an important treatment target that could help prevent patients from developing a serious heart condition in the future. In a study published last month in the European Journal of Heart Failure, the research team reported the identification of long-term patterns in levels of kidney health indicators in healthy European adults, and the impact of these patterns on the risk of new-onset heart failure. One in five people will develop HF in their lifetime, and impaired kidneys are one of the most critical risk factors for developing this condition. Because of this connection, it is common practice to monitor markers of kidney health in patients who are at risk of developing heart failure. "Day-to-day or short-term fluctuations in renal biomarkers are well-known," says lead author of the study Dr.Ryoto Sakaniwa. "However, the connection between long-term patterns in biomarker levels and the risk of heart failure is unknown." To address this, the researchers looked at levels of two common markers of kidney health -- urinary albumin excretion (UAE) and serum creatinine -- in almost 7000 patients from the Dutch study Prevention of Renal and Vascular End-stage Diseases (PREVEND). Patterns in UAE and serum creatinine levels were tracked over 11 years and investigated for their association with new-onset heart failure and death. "The results were very clear," explains Dr. Jasper Tromp, senior author. "While most participants had stable low UAE or serum creatinine, those with persistently high UAE had a statistically higher risk of new-onset heart failure or all-cause mortality. Interestingly, annual levels of renal biomarkers were remarkably stable year to year across the 11 years of follow up" Stable serum creatinine levels over time were associated with heart failure, but not with a higher risk of death. More detailed analysis showed that patients with persistently higher UAE or serum creatinine levels were more likely to be older and male, and to have conditions such as diabetes, previous heart attack, or dyslipidemia. "Our results highlight the importance of the heart-kidney link in heart failure by showing that patients with persistently worse renal function, as indicated by higher UAE or serum creatinine levels, are at a higher risk of heart failure or mortality," says Sakaniwa. "Reducing these renal biomarkers could help prevent heart failure." The findings from this study suggest that reducing UAE could help lower the risk of future heart failure and death in these patients. Given that one in five men and women will develop heart failure during their lifetime, these findings could have an important impact on preventive medicine and should be confirmed in non-European populations.

Teleflex (NYSE: TFX) + announced today that it completed patient enrollment in its prospective multicenter Ringer PTCA study. Ringer PTCA is one of two clinical studies evaluating Teleflex’s novel Ringer perfusion balloon catheter. The trial enrolled patients across seven leading complex percutaneous coronary intervention (PCI) centers in the U.S. and Canada. Dr. Kathleen Kearney of the University of Washington leads the trial. Kearney said in a news release that Ringer’s availability “is much anticipated by the interventional cardiology community.” She added that completed enrollment in the trial marks “a big step” toward that milestone. Wayne, Pennsylvania-based Teleflex said the study employed Ringer in selected coronary intervention patients who could benefit from continued perfusion during coronary balloon inflations. Parallel to Ringer PTCA, Teleflex has a 30-patient prospective study underway evaluating the safety and utility of Ringer. That study looks at Ringer for emergently managing coronary perforations complicating PCI procedures. Coronary perforations, though infrequent, can represent life-threatening events demanding rapid treatment, Teleflex said. No commercially available devices currently exist for temporarily controlling bleeding from coronary perforations pending definitive treatment or to seal perforations without leaving behind a permanent coronary implant, according to the company. “Completing enrollment is a significant milestone in the clinical validation and regulatory pathway to release the Ringer perfusion balloon catheter to treat patients,” said Teleflex Medical Director Dr. Christopher Buller.

Enrollment Complete in Study Evaluating the Performance of the Ringer™ Perfusion Balloon Catheter in Patients Undergoing Percutaneous Coronary InterventionsWAYNE, Pa., July 19, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the completion of patient enrollment in the prospective multicenter RingerTM PTCA study. RingerTM PTCA is one of two clinical studies evaluating the performance of the novel RingerTM Perfusion Balloon Catheter. The RingerTM PTCA study enrolled patients at seven leading complex PCI centers in the US and Canada. Led by Principal Investigator Kathleen Kearney M.D., University of Washington, the study employed the RingerTM Device in selected coronary intervention patients who could benefit from continued perfusion during coronary balloon inflations. “Completing enrollment is a significant milestone in the clinical validation and regulatory pathway to release the RingerTM Perfusion Balloon Catheter to treat patients,” said Teleflex Medical Director, Dr. Christopher Buller. Running in parallel to the RingerTM PTCA study is a 30-patient prospective study evaluating the safety and utility of RingerTM for emergently managing coronary perforations complicating PCI procedures. Coronary perforations, though infrequent, can be life-threatening events that demand rapid treatment. Currently there are no commercially available devices designed to temporarily control bleeding from coronary perforations pending definitive treatment or to seal perforations without leaving behind a permanent coronary implant. “Availability of RingerTM is much anticipated by the interventional cardiology community, and completion of enrollment in RingerTM PTCA puts us a big step closer to that goal,” said Kathleen Kearney M.D., University of Washington. About Teleflex IncorporatedTeleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com. Teleflex is the home of Arrow®, Deknatel®, LMA®, Pilling®, QuikClot®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose. Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. *Dr. Kearney is a paid consultant of Teleflex Incorporated. CAUTION: RingerTM is an investigational device and is limited by federal (or United States) law to investigational use. CAUTION: Federal (USA) law restricts these devices for sale or use by or on the order of a physician. Teleflex, the Teleflex logo, Arrow, Deknatel, GuideLiner, LMA, Pilling, QuikClot, Ringer, Rusch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates in the U.S. and/or other countries. Refer to the Instructions for Use for a complete listing of the indications, contraindications, warnings, and precautions. Information in this document is not a substitute for the product Instructions for Use. Not all products may be available in all countries. Please contact your local representative. © 2023 Teleflex Incorporated. All rights reserved. MC-009018. Contacts: For Teleflex Incorporated:Lawrence KeuschVice President, Investor Relations and Strategy Development investor.relations@teleflex.com610.948.2836